We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neurocrine Biosciences (NBIX - Free Report) ) has quietly become one of biotech's strongest earnings stories, combining impressive commercial execution with a rapidly improving profit outlook.
While many biotechnology companies remain years away from consistent profitability, Neurocrine has established itself as a cash-generating growth company thanks to the continued success of its flagship movement-disorder treatment, INGREZZA, an expanding commercial portfolio, and a promising late-stage pipeline.
Even more encouraging for investors, Wall Street analysts have become increasingly optimistic about the company's earnings prospects over the last two months.
A wave of upward earnings estimate revisions has helped propel NBIX to a Zacks Rank #1 (Strong Buy), signaling favorable near-term expectations.
Image Source: Zacks Investment Research
Neurocrine’s Compelling EPS Revisions
One of the strongest indicators behind Neurocrine's bullish outlook is the magnitude of recent earnings estimate revisions.
Over the last 60 days, analysts have steadily raised their profit forecasts across every major reporting period:
Current quarter EPS has increased from $1.82 to $2.25 (+23.6%)
Next quarter EPS has climbed from $2.23 to $2.46 (+10.3%)
Current fiscal year EPS has improved from $8.00 to $9.47 (+18.4%)
Next fiscal year EPS has increased from $9.48 to $10.79 (+13.8%)
Image Source: Zacks Investment Research
More impressive, estimate revisions have been almost entirely one-sided. According to Zacks data, all recent analyst revisions have moved higher, with virtually no downward revisions over the period.
That broad agreement among analysts is precisely the type of earnings momentum that the stock market and the Zacks Rank system reward, helping Neurocrine earn its coveted Zacks Rank #1 (Strong Buy).
INGREZZA Continues to Fuel Growth
Neurocrine's commercial success continues to revolve around INGREZZA, its market-leading treatment for movement disorders such as tardive dyskinesia and Huntington's disease chorea.
The company generated $2.86 billion in annual revenue during 2025, representing 22% year over year growth.
Furthermore, management expects another strong year in 2026, guiding for $2.7 billion to $2.8 billion in INGREZZA sales. Wall Street is equally optimistic, with analysts projecting Neurocrine's total revenue to climb 31% this year to $3.75 billion, followed by another 16% increase in FY27 to $4.34 billion.
INGREZZA is benefiting from:
Growing physician adoption
Expanded patient awareness
Strong reimbursement coverage
Continued penetration within existing indications
Meanwhile, Neurocrine is becoming less dependent on a single product as newer therapies, including CRENESSITY, are contributing to revenue while the company advances numerous late-stage neuroscience programs.
Record Results are Building Momentum
Neurocrine has continued to deliver operating results that justify analysts' rising expectations.
During Q1, the company posted record quarterly revenue of more than $800 million, driven by continued INGREZZA strength and an encouraging contribution from newer products. Management also reaffirmed its full-year sales outlook while highlighting multiple pipeline catalysts expected over the next several years.
Strong execution has translated directly into expanding profitability, which helps explain why analysts have become increasingly confident in Neurocrine's future earnings power.
Attractive Growth at a Reasonable Valuation
Despite trading near 52-week highs of $169 a share, Neurocrine stock still appears reasonably valued relative to its earnings outlook.
Shares trade at roughly 22X forward earnings, a very modest multiple for a biotechnology company expected to deliver double-digit earnings growth while generating substantial cash flow.
In comparison, Neurocrine’s Zacks Medical-Drugs Industry average is at over 90X forward earnings, which includes noteworthy pharmaceutical peers such as Collegium Pharmaceutical (COLL - Free Report) ), Indivior Pharmaceuticals (INDV - Free Report) ), and United Therapeutics (UTHR - Free Report) ).
Image Source: Zacks Investment Research
Reassuringly, Neurocrine's balance sheet remains healthy as well, with cash and equivalents of over $1.3 billion. Including marketable securities, the company has approximately $2.5 billion in liquidity available to fund continued research, business development, and pipeline expansion.
If Neurocrine continues to execute on both its commercial business and clinical pipeline, today's valuation could still leave plenty of room for additional upside.
Image Source: Zacks Investment Research
Summary & Conclusion
Biotechnology investing often revolves around binary clinical events, but Neurocrine Biosciences offers investors something different—a profitable commercial business with visible earnings growth supported by improving analyst sentiment.
Neurocrine has become one of the more attractive growth stories in the biotechnology space, thanks to continued strength from INGREZZA, the rollout of newer therapies, and a robust clinical pipeline.
For investors seeking a high-reward biotech stock with strong earnings momentum rather than speculative promise, NBIX is certainly worthy of consideration.
View the Zacks #1 Rank List
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX - Free Report) ) has quietly become one of biotech's strongest earnings stories, combining impressive commercial execution with a rapidly improving profit outlook.
While many biotechnology companies remain years away from consistent profitability, Neurocrine has established itself as a cash-generating growth company thanks to the continued success of its flagship movement-disorder treatment, INGREZZA, an expanding commercial portfolio, and a promising late-stage pipeline.
Even more encouraging for investors, Wall Street analysts have become increasingly optimistic about the company's earnings prospects over the last two months.
A wave of upward earnings estimate revisions has helped propel NBIX to a Zacks Rank #1 (Strong Buy), signaling favorable near-term expectations.
Image Source: Zacks Investment Research
Neurocrine’s Compelling EPS Revisions
One of the strongest indicators behind Neurocrine's bullish outlook is the magnitude of recent earnings estimate revisions.
Over the last 60 days, analysts have steadily raised their profit forecasts across every major reporting period:
Image Source: Zacks Investment Research
More impressive, estimate revisions have been almost entirely one-sided. According to Zacks data, all recent analyst revisions have moved higher, with virtually no downward revisions over the period.
That broad agreement among analysts is precisely the type of earnings momentum that the stock market and the Zacks Rank system reward, helping Neurocrine earn its coveted Zacks Rank #1 (Strong Buy).
INGREZZA Continues to Fuel Growth
Neurocrine's commercial success continues to revolve around INGREZZA, its market-leading treatment for movement disorders such as tardive dyskinesia and Huntington's disease chorea.
The company generated $2.86 billion in annual revenue during 2025, representing 22% year over year growth.
Furthermore, management expects another strong year in 2026, guiding for $2.7 billion to $2.8 billion in INGREZZA sales. Wall Street is equally optimistic, with analysts projecting Neurocrine's total revenue to climb 31% this year to $3.75 billion, followed by another 16% increase in FY27 to $4.34 billion.
INGREZZA is benefiting from:
Meanwhile, Neurocrine is becoming less dependent on a single product as newer therapies, including CRENESSITY, are contributing to revenue while the company advances numerous late-stage neuroscience programs.
Record Results are Building Momentum
Neurocrine has continued to deliver operating results that justify analysts' rising expectations.
During Q1, the company posted record quarterly revenue of more than $800 million, driven by continued INGREZZA strength and an encouraging contribution from newer products. Management also reaffirmed its full-year sales outlook while highlighting multiple pipeline catalysts expected over the next several years.
Strong execution has translated directly into expanding profitability, which helps explain why analysts have become increasingly confident in Neurocrine's future earnings power.
Attractive Growth at a Reasonable Valuation
Despite trading near 52-week highs of $169 a share, Neurocrine stock still appears reasonably valued relative to its earnings outlook.
Shares trade at roughly 22X forward earnings, a very modest multiple for a biotechnology company expected to deliver double-digit earnings growth while generating substantial cash flow.
In comparison, Neurocrine’s Zacks Medical-Drugs Industry average is at over 90X forward earnings, which includes noteworthy pharmaceutical peers such as Collegium Pharmaceutical (COLL - Free Report) ), Indivior Pharmaceuticals (INDV - Free Report) ), and United Therapeutics (UTHR - Free Report) ).
Image Source: Zacks Investment Research
Reassuringly, Neurocrine's balance sheet remains healthy as well, with cash and equivalents of over $1.3 billion. Including marketable securities, the company has approximately $2.5 billion in liquidity available to fund continued research, business development, and pipeline expansion.
If Neurocrine continues to execute on both its commercial business and clinical pipeline, today's valuation could still leave plenty of room for additional upside.
Image Source: Zacks Investment Research
Summary & Conclusion
Biotechnology investing often revolves around binary clinical events, but Neurocrine Biosciences offers investors something different—a profitable commercial business with visible earnings growth supported by improving analyst sentiment.
Neurocrine has become one of the more attractive growth stories in the biotechnology space, thanks to continued strength from INGREZZA, the rollout of newer therapies, and a robust clinical pipeline.
For investors seeking a high-reward biotech stock with strong earnings momentum rather than speculative promise, NBIX is certainly worthy of consideration.